InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.046 0.007 (17.95%)+
Announcement
Release
24 Jun 2026 9:35AM
Price at Release
$0.039
Full Release
download
Summary
Emyria Limited has reported positive early results from its new treatment program for treatment-resistant depression (TRD). The first cohort of 10 patients showed statistically significant reductions in depression and trauma symptoms, alongside improvements in quality of life and daily functioning. These findings were achieved in patients who previously did not respond to standard treatments, highlighting a major unmet need in mental health care. The program operates through Emyria's Empax Centre network and is supported by health funding. The Therapeutic Goods Administration's recent regulatory changes have expanded the program's accessibility. However, the small cohort size and variability in follow-up times suggest that further research is necessary to substantiate these promising early outcomes.
Key Points
  • Emyria's depression program shows positive early results.
  • First cohort of 10 patients showed significant reductions in symptoms.
  • Program targets treatment-resistant depression (TRD).
  • Supported by health funding and growing regulatory support.
  • Results presented at the International Mental Health Conference.
  • Therapeutic Goods Administration expanded prescriber pathway.
  • Further research needed due to small cohort size.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.